Gyre Therapeutics, Inc. has announced new employment agreements for its Chief Executive Officer, Ying Luo, and Chief Financial Officer, Thomas Eastling, as part of its strategy to ensure leadership continuity. This development is significant for the company as it underscores its commitment to stability and growth within the pharmaceutical preparations sector.
On October 16, 2026, Gyre entered into an employment agreement with Dr. Luo, who will continue to serve as CEO. The agreement stipulates an annual base salary of $500,000 and a targeted annual bonus of $150,000 for 2026, subject to the Board of Directors' discretion. Additionally, Dr. Luo will have access to Gyre's employee benefit plans.
In the event that Dr. Luo's employment is terminated without cause, or if he resigns for good reason, he will receive severance benefits including salary continuation and reimbursement for COBRA health coverage. Notably, if termination occurs within a specified timeframe surrounding a change of control, Dr. Luo is entitled to a lump sum payment equal to his annual salary and bonus, along with accelerated vesting of equity awards.
Similarly, the agreement with CFO Thomas Eastling, also effective October 16, 2026, provides for an annual salary of $339,066 and a targeted bonus of $70,000 for the year. Like Dr. Luo, Mr. Eastling's agreement includes provisions for severance in the event of termination without cause or resignation for good reason, ensuring he receives salary continuation and health coverage reimbursement.
The employment agreements for both executives highlight Gyre's strategic focus on retaining experienced leadership as it navigates the competitive landscape of the pharmaceutical sector. By securing its top executives, Gyre aims to strengthen its operational stability and enhance its market position against rivals.
Details regarding the specific terms of the employment agreements can be found in the attached exhibits to the SEC filing, which includes the full texts of the agreements.
As Gyre Therapeutics continues to develop its business strategy, the focus on leadership continuity may play a crucial role in its future endeavors within the pharmaceutical preparations industry.